BrainStorm Cell Therapeutics Inc.
Tel Aviv
463 articles about BrainStorm Cell Therapeutics Inc.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
4/16/2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule - April 11, 2024
4/11/2024
BrainStorm Cell Therapeutics Inc. announced that it received a notification letter on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market, indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550.
-
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
4/10/2024
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve.
-
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
4/9/2024
BrainStorm Cell Therapeutics Inc. announced that it received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment, on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis.
-
After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.
-
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
4/8/2024
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.
-
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
4/1/2024
BrainStorm Cell Therapeutics Inc. today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
-
Despite the approval of two novel therapies for this uniformly fatal neurodegenerative disease, experts say regulatory standards and expectations are still evolving.
-
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
2/27/2024
BrainStorm Cell Therapeutics Inc. announced that it will present a poster outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida.
-
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
2/23/2024
BrainStorm Cell Therapeutics Inc. announced that it has submitted a Special Protocol Assessment request to the U.S. Food and Drug Administration for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis.
-
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
2/13/2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland.
-
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
12/26/2023
Brainstorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.
-
BrainStorm Issues 2023 Letter to Shareholders
12/20/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, issued a Letter to shareholders.
-
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
12/7/2023
BrainStorm Cell Therapeutics Inc. today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).
-
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
11/20/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the US Food & Drug Administration has granted the company a meeting to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis.
-
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
11/17/2023
BrainStorm Cell Therapeutics Inc. today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE.
-
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
11/14/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
-
BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update
11/7/2023
BrainStorm Cell Therapeutics Inc. announced that it will hold a conference call on Tuesday, November 14th at 8:30 a.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2023 and provide a corporate update.